0001209191-24-003276.txt : 20240213 0001209191-24-003276.hdr.sgml : 20240213 20240213202536 ACCESSION NUMBER: 0001209191-24-003276 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240209 FILED AS OF DATE: 20240213 DATE AS OF CHANGE: 20240213 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lang Matthew CENTRAL INDEX KEY: 0001712069 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40502 FILM NUMBER: 24631403 MAIL ADDRESS: STREET 1: C/O MYOVANT SCIENCES INC. STREET 2: 2000 SIERRA POINT PARKWAY, 9TH FLOOR CITY: BRISBANE STATE: CA ZIP: 94005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Lyell Immunopharma, Inc. CENTRAL INDEX KEY: 0001806952 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 833006753 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 201 HASKINS WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650 695-0677 MAIL ADDRESS: STREET 1: 201 HASKINS WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2024-02-09 0 0001806952 Lyell Immunopharma, Inc. LYEL 0001712069 Lang Matthew C/O LYELL IMMUNOPHARMA, INC. 201 HASKINS WAY SOUTH SAN FRANICSCO CA 94080 0 1 0 0 Chief Business Officer 0 Common Stock 2024-02-09 4 A 0 50000 0.00 A 50000 D Option (right to buy) 1.80 2024-02-09 4 A 0 500000 0.00 A 2034-02-08 Common Stock 500000 500000 D The reported transaction involved the Reporting Person's receipt of a grant of performance-based restricted stock units, subject to vesting upon the achievement of specified performance criteria. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. 12.5% of the option shares shall vest on August 9, 2024, with the remaining option shares to vest in equal monthly installments over the following forty-two months. /s/ Matthew Lang 2024-02-13